Last edition
News about "Treatment-Resistant Depression"
Tasman Therapeutics and Osmind Partner to Advance R-107 for Depressive Disorders
Tasman Therapeutics and Osmind are partnering to advance R-107, an investigational oral extended-release ketamine therapy, through phase 3 trials for depressive disorders.
Treatment-resistant Depression | 13/08/2026 | By News Bureau
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.
Treatment-Resistant Depression | 07/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy